Orencia (abatacept), the first T-cell co-stimulation modulator for the treatment of rheumatoid arthritis was approved by the U.S. FDA on December 23, 2005. Orencia, a fully human soluble fusion protein, works by selectively modulating a co-stimulatory signal which is required for full T-cell activation. Activated T cells play a central role in the inflammatory cascade leading to the joint inflammation and destruction associated with rheumatoid arthritis.

Can Orencia be used alone, with methotrexate, or with one of the TNF blockers (e.g. Enbrel, Remicade, and Humira)? Here is what you need to know about Orencia (Abatacept) For Rheumatoid Arthritis.

• More About Orencia
• More About Biologic DMARDs
• TNF Blockers (Enbrel, Remicade, Humira) - Test Your Knowledge
• What's The Difference Between Orencia And Other Biologic Drugs?